The median overall survival was @ months ( @ % confidence interval -LSB- CI -RSB- , @ to @ ) among @ patients in the nivolumab group and @ months ( @ % CI , @ to @ ) among @ patients in the docetaxel group ( hazard ratio for death , @ ; @ % CI , @ to @ ; P = @ ) .